» Articles » PMID: 30867059

Human ADSC Xenograft Through IL-6 Secretion Activates M2 Macrophages Responsible for the Repair of Damaged Muscle Tissue

Overview
Publisher Biomed Central
Date 2019 Mar 15
PMID 30867059
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adipose-derived mesenchymal stromal cells (ADSCs) are multipotent stromal cells. The cells secrete a number of cytokines and growth factors and show immunoregulatory and proangiogenic properties. Their properties may be used to repair damaged tissues. The aim of our work is to explain the muscle damage repair mechanism with the utilization of the human adipose-derived mesenchymal stromal cells (hADSCs).

Methods: For the hADSCs isolation, we used the subcutaneous adipose tissue collected during the surgery. The murine hind limb ischemia was used as a model. The unilateral femoral artery ligation was performed on 10-12-week-old male C57BL/6NCrl and NOD SCID mice. The mice received PBS (controls) or 1 × 10 hADSCs. One, 3, 7, 14 and 21 days after the surgery, we collected the gastrocnemius muscles for the immunohistochemical analysis. The results were analyzed with relevant tests using the Statistica software.

Results: The retention time of hADSCs in the limb lasted about 14 days. In the mice receiving hADSCs, the improvement in the functionality of the damaged limb occurred faster than in the control mice. More new blood vessels were formed in the limbs of the mice receiving hADSCs than in limbs of the control mice. hADSCs also increased the infiltration of the macrophages with the M2 phenotype (7-AAD/CD45/F4/80/CD206) into the ischemic limbs. hADSCs introduced into the limb of mice secreted interleukin-6. This cytokine stimulates the emergence of the proangiogenic M2 macrophages, involved, among others, in the repair of a damaged tissue. Both macrophage depletion and IL-6 blockage suppressed the therapeutic effect of hADSCs. In the mice treated with hADSCs and liposomes with clodronate (macrophages depletion), the number of capillaries formed was lower than in the mice treated with hADSCs alone. Administration of hADSCs to the mice that received siltuximab (human IL-6 blocker) did not cause an influx of the M2 macrophages, and the number of capillaries formed was at the level of the control group, as in contrast to the mice that received only the hADSCs.

Conclusions: The proposed mechanism for the repair of the damaged muscle using hADSCs is based on the activity of IL-6. In our opinion, the cytokine, secreted by the hADSCs, stimulates the M2 macrophages responsible for repairing damaged muscle and forming new blood vessels.

Citing Articles

Blood flow restriction-enhanced platelet-rich plasma: A pilot randomised controlled trial protocol.

Ayyan M, Alladaboina S, Al-Dolaymi A, Boudier-Reveret M, Papakostas E, Marin Fermin T J Exp Orthop. 2025; 12(1):e70034.

PMID: 39822661 PMC: 11735946. DOI: 10.1002/jeo2.70034.


Bioengineering strategies for regeneration of skin integrity: A literature review.

Shiraishi M, Sowa Y, Sunaga A, Yamamoto K, Okazaki M Regen Ther. 2025; 28():153-160.

PMID: 39790492 PMC: 11713503. DOI: 10.1016/j.reth.2024.12.006.


Exploring Anti-Fibrotic Effects of Adipose-Derived Stem Cells: Transcriptome Analysis upon Fibrotic, Inflammatory, and Hypoxic Conditioning.

Frommer M, Langridge B, Beedie A, Jasionowska S, Awad L, Denton C Cells. 2024; 13(8.

PMID: 38667308 PMC: 11049044. DOI: 10.3390/cells13080693.


Investigation of Expanded Human Adipose-derived Stem Cell Dosage and Timing for Improved Defecation Function.

Mori R, Miyoshi N, Fujino S, Mizushima T, Yukimoto R, Ogino T In Vivo. 2024; 38(2):546-558.

PMID: 38418103 PMC: 10905476. DOI: 10.21873/invivo.13473.


The comparison of adipose-derived stromal cells (ADSCs) delivery method in a murine model of hindlimb ischemia.

Pilny E, Czapla J, Drzyzga A, Smolarczyk R, Matuszczak S, Jarosz-Biej M Stem Cell Res Ther. 2024; 15(1):27.

PMID: 38303049 PMC: 10836003. DOI: 10.1186/s13287-024-03634-2.


References
1.
Bassi E, Aita C, Camara N . Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand?. World J Stem Cells. 2011; 3(1):1-8. PMC: 3097934. DOI: 10.4252/wjsc.v3.i1.1. View

2.
Czapla J, Matuszczak S, Wisniewska E, Jarosz-Biej M, Smolarczyk R, Cichon T . Human Cardiac Mesenchymal Stromal Cells with CD105+CD34- Phenotype Enhance the Function of Post-Infarction Heart in Mice. PLoS One. 2016; 11(7):e0158745. PMC: 4945149. DOI: 10.1371/journal.pone.0158745. View

3.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S . The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011; 1813(5):878-88. DOI: 10.1016/j.bbamcr.2011.01.034. View

4.
Martinez F, Gordon S . The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. PMC: 3944738. DOI: 10.12703/P6-13. View

5.
Liew A, OBrien T . Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther. 2012; 3(4):28. PMC: 3580466. DOI: 10.1186/scrt119. View